Supporting Information

Cu(II)-Catalyzed formal [4+2] cycloaddition between quinone methides (QMs) and electron-poor 3-vinylindoles

Hong-Ming Huang,^a Xu-Yan Wu,^a Bo-Rong Leng,^a Yi-Long Zhu, ^{*a} Xin-Chao Meng,^a Yu Hong,^a Bo Jiang, ^{*b} De-Cai Wang^{*a}

^aSchool of Pharmaceutical, Nanjing Tech University, Nanjing, 210009, Jiangsu, P. R. China. E-mail: dcwang@njtech.edu.cn, zhuyilong_88@njtech.edu.cn
^bSchool of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, P. R. China. E-mail: jiangchem@jsnu.edu.cn (BJ) Fax: +8651683500065; Tel: +8651683500065

Context

General Information	S2
General Procedure for the Synthesis of Compounds 1	S2
General Procedure for the Synthesis of Compounds 2	S3
General Procedure for the Synthesis of Compounds 4	S3
General Procedure for the Synthesis of Compounds 3	S4
General Procedure for the Synthesis of Compounds 5	S4
Characterization data	S5
Copies of ¹ H , ¹³ C NMR and ¹⁹ F NMR Spectra of Products	S15

General Information

¹H NMR (¹³C NMR) spectra were measured on a Bruker DPX 400 MHz spectrometer in CDCl₃ with chemical shift (δ) given in ppm relative to TMS as internal standard [(s = singlet, d = doublet, t = triplet, brs = broad singlet, m = multiplet), coupling constant (Hz)]. High-resolution mass spectra (HRMS) were obtained on an Agilent mass spectrometer using ESI-TOF (electrospray ionization-time of flight). X-Ray crystallographic analysis was performed with a Siemens SMART CCD and a Siemens P4 diffractometer. Column chromatography was generally performed on silica gel (200-300 mesh) and reactions were monitored with thin-layer chromatography (TLC) using 254 nm UV light. The melting points were measured with digital melting point detector.

General Procedure for the Synthesis of Compounds 1

Example for the Synthesis of 1a:

$$\begin{array}{c} & & \\ & &$$

A solution of 2-hydroxybenzaldehyde (10.0 mmol) and 1H-imidazole (20.0 mmol, 1.37 g) in CH₂Cl₂ (40 mL) was placed into a 100mL reaction vial, which was sealed at 0 °C. Then, TBSCl (1.2 equiv, 1.80 g) was added by dropwise slowly. The reaction mixture was stirred overtime. After that, a saturated NaHCO₃ solution was added dropwise to quench the reaction. The resulting solution was extracted with acetic ester (3×30 mL). Then the combined organic phases were washed with brine and dried over anhydrous Na₂SO₄, resulting in a white viscous liquid and used directly in the next step without purification.¹



A solution of phenols (2.2 mmol, 453 mg) and aldehydes (2.0 mmol, 472 mg) in toluene (10 mL) was placed in a Dean-Stark apparatus which was heated to reflux. Piperidine (2.0 equiv, 341 mg) was added by dropwise slowly. Then, the temperature was raised to 140°C and stirred for 12 h. After that, the reaction mixture was cooled to 120°C and acetic anhydride (2.0 equiv, 408 mg) was added by dropwise. The stirring was continued for 30 min and the solution was poured on ice-water and extracted with ethyl acetate (3 × 20 mL). The organic phases were combined, washed with brine and dried over anhydrous Na₂SO₄. Then the solvent was evaporated under reduced pressure and the corresponding products **A** (551mg, 65% yield) were obtained after flash column chromatography.²

To a solution of **A** (1 mmol, 424 mg) in THF (10 mL) at 0°C was added tetrabutylammonium fluoride trihydrate (TBAF 1.1 equiv, 1.1 mL). The reaction mixture was stirred for 10 min and a saturated NH₄Cl solution was added by dropwise to quench the reaction. The resulting solution was extracted with ethyl acetate (3×20 mL). Then the combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed to give the crude product which was purified by flash column chromatography to afford the desired compound **1a** (254 mg, 82% yield).

General Procedure for the Synthesis of Compounds 2

Example for the Synthesis of 2a:



To a solution of aldehyde (1 equiv) in anhydrous CH_2Cl_2 was added dry $Ph_3P=CHCO_2Et$ (1.5equiv) and stirred magnetically for 6 h at rt. Solvent was evaporated and residue was purified by flash chromatography over silica gel column.³

General Procedure for the Synthesis of Compounds 4

Example for the Synthesis of 4a:



To a solution of salicylaldehyde (10 mmol, 1 equiv) in THF (50 mL) at 0°C was added a solution of phenylmagnesium bromide in THF (30 mmol, 3 equiv) dropwise. The reaction was then removed from ice and stirred for 2 hours at rt. Upon completion, the reaction was then quenched at 0°C with saturated aqueous NH₄Cl solution. It was then extracted with EtOAc (3 x 25 mL) and the combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated. Purification by silica gel chromatography yielded the product as an off-white solid.⁴

Reference

- 1. X.-G. Song, S.-F. Zhu, X.-L. Xie and Q.-L. Zhou, Angew. Chem. Int. Ed., 2013, 52, 2555.
- 2. K. Zhao, Y. Zhi, T. Shu, A. Valkonen, K. Rissanen and D. Enders, Angew. Chem. Int. Ed., 2016, 55,12104.
- 3. D. H. Dethe, R. Boda and S. Das, Chem. Commun., 2013, 49, 3260.
- 4. C. R. Wong, G. Humme, Y. Cai, S. E. Schaus, J. S. Panek, Org. Lett., 2019,21,32.

General Procedure for the Synthesis of Compounds 3

Example for the Synthesis of **3a**:



To a solution of **1a** (0.2 mmol, 1 equiv) and **2a** (0.2 mmol, 1 equiv) in anhydrous CH_2Cl_2 (2 mL) at the room temperature was added $Cu(OTf)_2$ (0.1 equiv). The reaction was stirred for 12 h and monitored by TLC in 3:1 Hexanes:EtOAc. Upon completion, Purification by silica gel chromatography yielded **3a** as a white solid.

General Procedure for the Synthesis of Compounds 5

Example for the Synthesis of 5a:



To a solution of 4a (0.50 mmol, 1 equiv) and 2a (0.60 mmol, 1.2 equiv) in anhydrous CH₂Cl₂(5 mL) at the room temperature was added Cu(OTf)₂ (0.1 equiv). The reaction was stirred for 12 h and monitored by TLC in 3:1 Hexanes:EtOAc. Upon completion, Purification by silica gel chromatography yielded **5a** as a white solid.

Characterization data

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1H-indol-3-yl)chromane-3-carboxylate (3a).



White solid, mp 181 -182°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.07 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.31-7.22 (m, 1H), 7.16-6.74 (m, 9H), 5.60 (d, J = 11.2 Hz, 1H), 5.05 (s, 1H), 4.51-4.40 (m, 1H), 3.67-3.32 (m, 3H), 1.32 (s, 18H), 0.67 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.8, 154.5, 152.8, 136.2, 135.3, 132.7, 130.5, 128.1, 126.1, 125.9, 125.4, 123.5, 123.3, 122.3, 120.7, 119.9, 119.7, 116.7, 111.3, 67.9, 60.0, 50.3, 44.7, 34.3, 30.4, 13.5. IR (KBr, ν , cm⁻¹) 3627, 3435, 2954, 1735, 1433,

1240, 1161, 1007, 749. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₉NO₄ [M+Na]⁺ 548.2771, found 548.2776.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-6-fluoro-2-(1*H*-indol-3-yl)chromane-3-carboxylate (3b).



White solid, mp 139-140°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.07 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.34-7.23 (m, 1H), 7.16-6.98 (m, 3H), 6.96-6.66 (m, 5H), 5.58 (d, J = 10.8 Hz, 1H), 5.08 (s, 1H), 4.47-4.39 (m, 1H), 3.64-3.31 (m, 3H), 1.33 (s, 18H), 0.67 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.6, 157.0 (d, J = 236.9 Hz), 153.0, 150.6 (d, J = 1.9 Hz), 136.2, 136.0, 135.5, 132.04, 126.1, 125.8, 124.6, 123.3, 122.3, 119.8 (d, J = 39.8 Hz), 117.7 (d, J = 8.0 Hz), 116.1 (d, J = 22.8

Hz), 115.2 (d, *J* = 23.4 Hz), 114.8, 113.7, 111.3, 68.1, 60.2, 50.1, 44.7, 34.3, 30.3, 13.4. ¹⁹F NMR (376 MHz, CDCl₃; δ, ppm): -123.9(s). IR (KBr, *ν*, cm⁻¹) 3623, 3341, 2958, 1720, 1490, 1434, 1233, 1176, 1019, 745. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈FNO₄ [M+Na]⁺ 566.2677, found 566.2682.

Ethyl 6-chloro-4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1H-indol-3-yl)chromane-3-carboxylate(3c).



White solid, mp 175–177°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.07 (s, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.31-6.99(m, 6H), 6.89-6.75 (m, 3H), 5.60 (d, J = 11.2 Hz, 1H), 5.09 (s, 1H), 4.48-4.34 (m, 1H), 3.66-3.23 (m, 3H), 1.33 (s, 18H), 0.68 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm)170.4, 153.1, 153.0, 136.2, 135.5, 131.8, 129.8, 128.3, 126.0, 125.8, 125.3, 125.3, 123.3, 122.4, 120.0, 119.5, 118.1, 114.7, 111.4, 68.3, 60.2, 49.9, 44.5, 34.3, 30.3, 13.5. IR (KBr, v, cm⁻¹) 3640, 3374, 2959,

1719, 1478, 1435, 1236, 1006, 737. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈ClNO₄ [M+Na]⁺ 582.2382, found 582.2386.

Ethyl 6-bromo-4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1*H*-indol-3-yl)chromane-3-carboxylate



(3d).

(**3e**).

(3f).

White solid, mp 169–170°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.08 (s, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.31-7.19 (m, 2H), 7.17-6.93 (m, 4H), 6.87-6.73 (m, 3H), 5.60 (d, J = 10.8 Hz, 1H), 5.09 (s, 1H), 4.46-4.39 (m, 1H), 3.62-3.29 (m, 3H), 1.33 (s, 18H), 0.69 (t, J = 7.2 Hz, 3H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.4, 153.7, 153.0, 136.2, 135.6, 132.7, 131.8, 131.2, 126.0, 125.8, 125.7, 123.4, 122.4, 120.0,

119.5, 118.6, 114.6, 112.6, 111.4, 68.3, 60.2, 49.8, 44.5, 34.3, 30.3, 13.5. IR (KBr, *v*, cm⁻¹) 3631, 3375, 2957, 1719, 1475, 1434, 1225, 1001, 737. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈BrNO₄ [M+Na]⁺ 626.1876, found 626.1884.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1*H*-indol-3-yl)-6-methylchromane -3-carboxylate



White solid, mp 183-184°C; ¹H NMR (400 MHz, CDCl₃; *δ*, ppm) 8.06 (s, 1H), 7.55 (d, *J* = 7.6 Hz, 1H), 7.28-7.19 (m, 1H), 7.15-6.97 (m, 3H), 6.94-6.60 (m, 5H), 5.58 (d, *J* = 12.8 Hz, 1H), 5.06 (s, 1H), 4.47-4.40 (m, 1H), 3.69-3.22 (m, 3H), 2.16 (s, 3H), 1.33 (s, 18H), 0.66 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; *δ*, ppm) 170.9, 152.8, 152.3, 136.2, 135.3, 132.8, 130.6, 129.7, 129.0, 126.2, 125.9, 123.3,

123.0, 122.2, 119.8, 119.7, 116.4, 115.1, 111.3, 67.7, 60.1, 50.4, 44.8, 34.3, 30.4, 20.6, 13.5. IR (KBr, *v*, cm⁻¹) 3631, 3369, 2957, 1711, 1496, 1434, 1225, 1027, 739. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₄₁NO₄ [M+Na]⁺ 562.2928, found 562.2938.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1*H*-indol-3-yl)-6-methoxychromane-3-carboxylate



White solid, mp 160-162°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.02 (s, 1H), 7.23 (d, J = 2.4 Hz, 1H), 7.20-7.03 (m, 3H), 6.93-6.85 (m, 3H), 6.84-6.72 (m, 3H), 5.51 (d, J = 10.4 Hz, 1H), 5.04 (s, 1H), 3.78 (s, 3H), 4.47 (d, J = 11.2 Hz, 1H), 3.67-3.51 (m, 2H), 3.36 (t, J = 10.4 Hz, 1H), 1.32 (s, 18H), 0.57 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.3, 154.9, 154.3, 152.8, 135.8, 131.8,

131.4, 129.8, 127.7, 126.6, 125.4, 125.3, 123.7, 120.7, 116.7, 113.7, 112.8, 111.9, 101.4, 73.6, 60.1, 55.9, 53.8, 47.5, 34.3, 30.4, 13.7. IR (KBr, *v*, cm⁻¹) 3615, 3309, 2959, 1716, 1493, 1434, 1233, 1024, 744. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₄₁NO₅ [M+Na]⁺ 578.2877, found 578.2886.

Ethy 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(1*H*-indol-3-yl)-7-methoxychromane-3-carboxylate



(3g).

White solid, mp 164–165°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.10 (s, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.35-7.23 (m, 2H), 7.17-7.04 (m, 2H), 6.88 (s, 2H), 6.70 (dd, J = 8.8, 1.2 Hz, 1H), 6.44 (d, J = 2.8 Hz, 1H), 6.37 (dd, J = 8.4, 2.4 Hz, 1H), 5.53 (d, J = 10.4 Hz, 1H), 5.03 (s, 1H), 4.40 (dd, J = 11.2, 1.2 Hz, 1H), 3.69 (s, 3H), 3.63-3.48 (m, 2H), 3.33 (dd, J = 12.0, 8.0 Hz, 1H), 1.32 (s, 18H), 0.55 (t, J =

6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ, ppm) 172.3, 159.2, 155.6, 152.8, 136.3, 135.7, 131.9, 130.4, 126.0, 125.3, 123.2, 122.5, 120.1, 119.9, 117.4, 113.9, 111.2, 108.0, 100.9, 74.0, 60.1, 55.3, 54.1, 47.1, 34.3, 30.4, 13.6. IR (KBr, ν, cm⁻¹) 3629, 3394, 2957, 1721, 1486, 1435, 1229, 753. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₄₁NO₅ [M+Na]⁺ 578.2877, found 578.2884.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(5-fluoro-1*H*-indol-3-yl)chromane-3-carboxylate(3h).



White solid , mp 192–194°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.17 (s, 1H), 7.36 (dd, J = 9.6, 2.4Hz, 1H), 7.24 (s, 1H), 7.21-7.13 (m, 1H), 7.12-7.05 (m, 1H), 6.92-6.73 (m, 6H), 5.47 (d, J = 10.4 Hz, 1H), 5.05 (s, 1H), 4.46 (d, J = 11.2 Hz, 1H), 3.66-3.50 (m, 2H), 3.32 (t, J = 12.0, 1H), 1.32 (s, 18H), 0.58 (t, J = 8.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.3, 158.0 (d, J = 233.5 Hz), 153.8 (d, J = 184.1 Hz), 135.9, 132.8, 131.6, 129.8, 127.8, 126.4, 126.3, 125.4, 125.2, 124.9, 120.8, 116.7, 114.1 (d, J

= 4.7 Hz), 111.9 (d, J = 9.6 Hz), 111.0 (d, J = 26.3 Hz), 104.9 (d, J = 23.8 Hz), 73.7, 60.2, 54.0, 47.5, 34.3, 30.4, 13.7. ¹⁹F NMR (376 MHz, CDCl₃; δ , ppm): -123.8(s). IR (KBr, v, cm⁻¹) 3620, 3353, 2961, 1721, 1458, 1435, 1229, 1161,1007, 623. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈FNO₄ [M+Na]⁺ 566.2677, found 566.2683.

Ethyl 2-(5-chloro-1*H*-indol-3-yl)-4-(3,5-di-tert-butyl-4-hydroxyphenyl) chromane-3-carboxylate(3i).



White solid, mp 176-178°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.14 (s, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.27-7.19 (m, 1H), 7.18-6.91 (m, 4H), 6.93-6.75 (m, 4H), 5.55 (d, J = 10.8 Hz, 1H), 5.08 (s, 1H), 4.52-4.45 (m, 1H), 3.68-3.25 (m, 3H), 1.34 (s, 18H), 0.70 (t, J = 7.2 Hz, 3H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) δ 170.7, 154.3, 152.9, 135.4, 134.4, 132.7, 130.6, 128.2, 127.2, 125.9, 125.4, 124.7, 122.9, 122.7, 120.9, 119.2, 116.7, 114.9, 112.3, 67.5, 60.2, 50.6, 44.6, 34.3, 30.4, 13.4. IR (KBr, v, cm⁻¹)3628, 3402, 2956,

1734, 1433, 1229, 1114, 1036, 1006, 799, 754. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈ClNO₄ [M+Na]⁺ 582.2382, found 582.2390.

Ethyl 2-(5-bromo-1*H*-indol-3-yl)-4-(3,5-di-tert-butyl-4 hydroxyphenyl)chromane-3-carboxylate(3j).



White solid, mp 196-197°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.16 (s, 1H), 7.85 (d, J = 1.6 Hz, 1H), 7.29-7.20 (m, 2H), 7.18-7.05 (m, 2H), 6.92-6.85 (m, , 3H), 6.84-6.74 (m, 2H), 5.48 (d, J = 10.4 Hz, 1H), 5.05 (s, 1H), 4.47 (d, J = 11.4 Hz, 1H), 3.68-3.54 (m, 2H), 3.30 (dd, J = 12.0, 8.0 Hz, 1H), 1.33 (s, 18H), 0.61 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.2, 154.6, 152.9, 135.8, 134.9, 131.6, 129.8, 127.8, 127.7, 125.5, 125.4, 125.2, 124.3, 122.5, 120.9, 116.7, 113.8, 113.5, 112.7, 73.5, 60.3,

54.0, 47.5, 34.3, 30.4, 13.7. IR (KBr, v, cm⁻¹) 3629, 3400, 2956, 1736, 1432, 1228, 1113, 1037, 797, 752. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈BrNO₄ [M+Na]⁺ 626.1876, found 626.1881.

Ethyl 2-(5-cyano-1H-indol-3-yl)-4-(3,5-di-tert-butyl-4-hydroxyphenyl)chromane-3-carboxylate(3k).



White solid, mp 211 -213°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.67 (s, 1H), 8.18 (s, 1H), 7.49-7.27 (m, 3H), 7.24-6.76 (m, 6H), 5.59 (d, J = 10.4 Hz, 1H), 5.14 (s, 1H), 4.60-4.48 (m, 1H), 3.77-3.29 (m, 3H), 1.40 (s, 18H), 0.66 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) δ 172.2, 154.4, 153.0, 137.9, 135.9, 131.3, 129.8, 127.9, 125.9, 125.8, 125.5, 125.4, 125.1, 121.1, 120.7, 116.6, 115.0, 112.3, 103.3, 73.5, 34.3, 30.4, 26.9, 13.7. IR (KBr, v, cm⁻¹) 3611, 3332, 2924, 2218, 1710, 1471,

1374, 808, 756. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₃₈N₂O₄ [M+Na]⁺ 573.2724, found 573.2736.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(5-methyl-1H-indol-3-yl)chromane-3-carboxylate(3l).



White solid, mp 205–206°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 7.99 (s, 1H), 7.48 (s, 1H), 7.22 (d, J = 2.4Hz, 1H), 7.16 (s, 1H), 7.10-7.04 (m, 1H), 6.97-6.93 (m, 1H), 6.91-6.85 (m, 3H), 6.83-6.73 (m, 2H), 5.51 (d, J = 10.4 Hz, 1H), 5.03 (s, 1H), 4.47 (d, J = 11.6 Hz, 1H), 3.65-3.50 (m, 2H), 3.36 (dd, J = 11.6, 10.0 Hz, 1H), 2.38 (s, 3H), 1.32 (s, 18H), 0.57 (t, J = 8.0 Hz, 3H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.3, 154.9, 152.8, 135.8, 134.6, 131.8, 129.8, 129.3, 127.6, 126.4, 125.5, 125.3, 124.2,

123.2, 120.6, 119.4, 116.7, 113.5, 110.9, 73.7, 60.1, 53.8, 47.6, 34.3, 30.4, 21.6, 13.7. IR (KBr, v, cm⁻¹) 3629, 3381, 2955, 1721, 1432, 1230, 1156, 800, 755. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₄₁NO₄ [M+Na]⁺ 562.2928, found 562.2934.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(5-methoxy-1*H*-indol-3-yl)chromane-3-carboxylate



CDCl₃; *δ*, ppm) 172.4, 153.5, 152.8, 149.2, 136.3, 135.8, 131.6, 126.1, 125.4, 123.1, 122.5, 120.1, 119.9, 117.3,114.6,114.1,113.6,111.2, 73.8, 60.1, 55.8, 54.1, 47.7, 34.3, 30.4, 30.4,13.6. IR (KBr, *v*, cm⁻¹) 3614, 3311, 2959, 1715, 1493, 1434, 1208, 1024, 744. HR-MS (ESI-TOF, m/z) calcd for C₃₅H₄₁NO₅ [M+Na]⁺ 578.2877, found 528.2886.

Ethyl 2-(4-chloro-1*H*-indol-3-yl)-4-(3,5-di-tert-butyl-4-hydroxyphenyl) chromane -3-carboxylate



(**3**n).

White solid, mp 210-212°C; ¹H NMR (400 MHz, CDCl₃; δ, ppm) 8.42 (s, 1H), 7.43 (s, 1H), 7.26-7.21 (m, 1H), 7.21-7.06 (m, 3H), 7.04-6.79 (m, 5H), 6.23-5.97 (m, 1H), 5.11 (s, 1H), 4.61-4.49 (m, 1H), 3.98-3.45 (m, 3H), 1.40 (s, 18H), 0.76 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ, ppm) 172.3, 154.7, 152.8, 135.9, 132.2, 129.8, 127.6, 126.3, 125.4, 123.7, 123.0, 121.7, 120.6, 116.7, 114.1, 110.1, 68.1, 60.3, 53.7, 47.8,

34.3, 30.4, 13.8. IR (KBr, v, cm⁻¹) 3626, 3432, 2961, 1715, 1486, 1434, 1229, 1179, 1015, 738. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈ClNO₄ [M+Na]⁺ 582.2382, found 582.2395.

Ethyl 2-(6-chloro-1*H*-indol-3-yl)-4-(3,5-di-tert-butyl-4-hydroxyphenyl) chromane-3-carboxylate (30).



White solid, mp 200-201°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.21 (s, 1H), 7.46 (d, J = 8.8 Hz, 1H), 7.25-7.19 (m, 1H), 7.16-6.96 (m, 3H), 6.94-6.74 (m, 5H), 5.50 (d, J = 10.0 Hz, 1H), 5.06 (s, 1H), 4.51-4.46 (m, 1H), 3.66-3.27 (m, 3H), 1.33 (s, 18H), 0.57 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.3, 154.7, 152.9, 136.6, 135.9, 131.6, 129.8, 128.2, 127.8, 125.9, 125.2, 124.1, 123.9, 120.9, 120.8, 120.5, 116.6, 114.1, 111.2, 73.7, 60.3, 47.5, 34.3, 34.3, 30.4, 13.7. IR (KBr, v, cm⁻¹) 3624, 3415,

2961, 1735, 1486, 1434, 1231, 1114, 1018, 754. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈ClNO₄ [M+Na]⁺ 582.2382, found 582.2386.

Ethyl 4-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(6-fluoro-1*H*-indol-3-yl) chromane-3-carboxylate (3p).



White solid, mp 183-184°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.09 (s, 1H), 7.45 (dd, J = 8.8, 5.2 Hz, 1H), 7.23-7.04 (m, 2H), 7.04-6.72 (m, 7H), 5.55 (d, J = 12.0 Hz, 1H), 5.06 (s, 1H), 4.50-4.41 (m, 1H), 3.64-3.27 (m, 3H), 1.32 (s, 18H), 0.68 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 172.3, 160.3 (d, J = 243.0 Hz), 153.8 (d, J = 192.7 Hz), 136.2 (d, J = 12.4 Hz), 135.9, 131.7, 129.8, 127.7, 125.4, 125.3, 123.4 (d, J = 3.4 Hz), 122.5, 120.8, 120.7, 116.6, 114.2, 109.0 (d, J = 24.4 Hz),

97.5 (d, J = 26.0 Hz), 73.8, 60.2, 54.1, 47.5, 34.3, 30.4, 13.7. ¹⁹F NMR (376 MHz, CDCl₃; δ , ppm): - 120.6(s). IR (KBr, v, cm⁻¹) 3630 , 3411, 2959, 1735, 1486, 1433, 1228, 1142, 1015, 755. HR-MS (ESI-TOF, m/z) calcd for C₃₄H₃₈FNO₄ [M+Na]⁺ 566.2677, found 566.2686.

1-(4-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-(1*H*-indol-3-yl) chroman-3-yl)ethan-1-one (3q).



Yellow solid, mp 158-160°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.13 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.32-7.26 (m, 1H), 7.17-7.04 (m, 4H), 6.91-6.84 (m, 3H), 6.83-6.73 (m, 2H), 5.36 (d, J = 12.0 Hz, 1H), 5.06 (s, 1H), 4.40 (d, J = 12.0 Hz, 1H), 3.73 (t, J = 12.0 Hz, 1H), 1.32 (s, 18H), 1.20 (s, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 210.7, 154.8, 152.7, 136.6, 136.2, 132.1, 129.7, 127.6, 125.7, 125.5, 125.2, 123.5, 122.6, 120.6, 120.3, 120.1, 116.7, 113.7, 111.5, 74.5, 58.9, 47.3, 34.4, 33.2, 30.4. IR (KBr, v, cm⁻¹)

3600, 3449, 2960, 1707, 1433, 1230, 741. HR-MS (ESI-TOF, m/z) calcd for $C_{33}H_{37}NO_3$ [M+Na]⁺ 518.2666, found 518.2671.

4-(2-(1H-indol-3-yl)-3-nitrochroman-4-yl)-2,6-di-tert butylphenol (3r).



Yellow solid, mp 185 -187°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.17 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.34-7.26 (m, 1H), 7.27-7.04 (m, 5H), 6.94-6.80 (m, 4H), 5.70-5.62 (m, 1H), 5.29 (t, J = 10.4 Hz, 1H), 5.12 (s, 1H), 4.84 (d, J = 10.8 Hz, 1H), 1.32 (s, 18H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) 152.5, 135.3, 128.9, 127.3, 124.9, 124.2, 122.9, 121.9, 120.8, 119.6, 118.4, 115.8, 110.5, 90.2, 73.2, 48.2, 33.3, 29.3. IR (KBr, v, cm⁻¹) 3616, 3431, 2957, 1553, 1434, 1225, 748. HR-MS (ESI-TOF, m/z) calcd for

 $C_{31}H_{34}N_2O_4 [M+Na]^+ 521.2411$, found 521.2418.

Ethyl 2-(1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5a).



White solid Yield, mp 90-92°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.09 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.28-7.18 (m, 4H), 7.18-6.95 (m, 7H), 6.95-6.72 (m, 2H), 5.63 (d, J = 10.8 Hz, 1H), 4.63-4.54 (m, 1H), 3.79-3.47 (m, 3H), 0.77 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.7, 154.7, 142.0, 136.3, 130.4, 129.5, 128.4, 128.3, 127.2, 125.9, 123.8, 123.0, 122.3, 120.9, 119.9, 119.9, 117.0, 114.4,

111.4, 68.3, 60.3, 49.7, 44.6, 27.0, 13.6. IR (KBr, *v*, cm⁻¹) 3409, 3058, 3028, 2979, 2931, 1726, 1486, 1454, 1243, 1010, 745. HR-MS (ESI-TOF, m/z) calcd for C₂₆H₂₃NO₃ [M+Na]⁺ 420.1570, found 420.1570.

Ethyl 2-(1*H*-indol-3-yl)-6-methyl-4-phenylchromane-3-carboxylate(5b).



White solid, mp 122-124°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.06 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.28-7.18 (m, 2H), 7.19-6.71 (m, 10H), 5.57 (d, J = 11.2 Hz, 1H), 4.50 (d, J = 6.0 Hz, 1H), 3.75-3.40 (m, 3H), 2.13 (s, 3H), 0.72 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.8, 152.5, 142.1, 136.3, 130.5, 130.1, 129.5, 129.3, 128.7, 128.3, 127.2, 125.9, 123.8, 122.6, 122.2, 119.9, 119.9, 116.7, 114.4, 111.5, 68.2, 60.3, 49.8, 44.7, 20.6, 13.6. IR (KBr, v, cm⁻¹)

3426, 3054, 3028, 2986, 2958, 2903, 1717, 1497, 1454, 1217, 971, 742. HR-MS (ESI-TOF, m/z) calcd for C₂₇H₂₅NO₃ [M+Na]⁺ 434.1727, found 434.1734.

Ethyl 2-(1*H*-indol-3-yl)-6-methoxy-4-phenylchromane-3-carboxylate(5c).



White solid, mp 134-135°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.16 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.32-7.20 (m, 4H), 7.22-6.99 (m, 5H), 6.96-6.70 (m, 2H), 6.54 (d, J = 2.8 Hz, 1H), 5.64 (d, J = 11.2 Hz, 1H), 4.58 (d, J = 6.0 Hz, 1H), 3.78 (dd, J = 11.2, 6.0 Hz, 1H), 3.67 (s, 3H), 3.63-3.49 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.7, 153.7, 148.9, 141.8,

136.3, 129.5, 128.3, 127.3, 125.9, 123.7, 123.4, 122.2, 119.9, 117.7, 115.2, 114.5, 114.2, 111.4, 68.2, 60.2, 55.7, 49.9, 44.9, 13.6. IR (KBr, *v*, cm⁻¹) 3408, 3062, 3027, 2953, 2833, 1727, 1494, 1455, 1214, 1035, 743. HR-MS (ESI-TOF, m/z) calcd for C₂₇H₂₅NO₄ [M+Na]⁺ 450.1676, found 450.1681.

Ethyl 2-(1*H*-indol-3-yl)-4-(p-tolyl)chromane-3-carboxylate(5d).



White solid, mp 90-91°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.06 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 9.2 Hz, 1H), 7.18-6.87 (m, 10H), 6.87-6.73 (m, 1H), 5.63 (d, J = 11.2 Hz, 1H), 4.53 (d, J = 6.0 Hz, 1H), 3.77-3.42 (m, 3H), 2.26 (s, 3H), 0.80 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.7, 154.6, 138.9, 136.8, 136.3, 130.3, 129.3, 129.0, 128.3, 126.0, 123.7, 123.3, 122.2, 120.8, 120.0, 119.9, 116.9, 114.6, 111.3, 68.3, 60.2, 49.6, 44.2, 21.1, 13.6. IR (KBr, v, cm⁻¹) 3407, 3056,

2980, 2924, 2869, 1723, 1486, 1455, 1227, 1011, 744. HR-MS (ESI-TOF, m/z) calcd for C₂₇H₂₅NO₃ [M+Na]⁺ 434.1727, found 434.1732.

Ethyl 2-(1*H*-indol-3-yl)-4-(o-tolyl)chromane-3-carboxylate(5e).



White solid, mp 128-129°C; ¹H NMR (400 MHz, CDCl₃; δ, ppm) 8.07 (s, 1H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.29-7.20 (m, 1H), 7.17-7.00 (m, 8H), 6.99-6.73 (m, 3H), 5.76 (d, *J* = 10.8 Hz, 1H), 4.90 (d, *J* = 6.0 Hz, 1H), 3.77 (dd, *J* = 10.8, 6.2 Hz, 1H), 3.61-3.44 (m, 2H), 2.35 (s, 3H), 0.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ, ppm) 171.0, 154.7, 140.7, 136.317, 136.2, 130.7, 130.4, 130.2, 128.1, 126.8, 126.1, 125.9, 124.0, 123.5, 122.4, 120.9, 112.0, 119.9, 117.0, 114.2, 111.4, 68.6, 60.3, 49.4, 38.9,

19.9, 13.4. IR (KBr, v, cm⁻¹) 3385, 3024, 2978, 2952, 2898, 1720, 1486, 1453, 1228, 1017, 748. HR-MS (ESI-TOF, m/z) calcd for $C_{27}H_{25}NO_3$ [M+Na]⁺ 434.1727, found 434.1731.

Ethyl 2-(5-fluoro-1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5f).



White solid, mp 178-179°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.18 (s, 1H), 7.48-7.17 (m, 6H), 7.18-7.10 (m, 3H), 7.06-6.75 (m, 4H), 5.62 (d, J = 11.2 Hz, 1H), 4.63 (d, J = 5.6 Hz, 1H), 3.79-3.45 (m, 3H), 0.83 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.6, 157.90 (d, J = 234.9 Hz), 154.5, 141.9, 132.7, 130.4, 129.5, 128.5, 128.3, 127.3, 126.3 (d, J = 10.2 Hz), 125.4, 122.9, 121.0, 116.9, 114.7 (d, J = 4.7 Hz), 112.0 (d, J = 9.7 Hz), 110.8 (d, J = 26.6 Hz), 104.8 (d, J = 24.0 Hz), 68.0,

60.4, 49.7, 44.6, 13.6. ¹⁹F NMR (376 MHz, CDCl₃; δ, ppm): -124.0(s). IR (KBr, *v*, cm⁻¹) 3430, 3062, 3032, 2981, 2934, 2895, 1715, 1488, 1454, 1242, 1032, 753. HR-MS (ESI-TOF, m/z) calcd for C₂₆H₂₂FNO₃ [M+Na]⁺ 438.1476, found 438.1481.

Ethyl 2-(5-chloro-1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5g).



White solid, mp 178-180°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.15 (s, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.27-7.18 (m, 3H), 7.17-7.02 (m, 6H), 6.99-6.69 (m, 3H), 5.54 (d, J = 11.2 Hz, 1H), 4.59-4.53 (m, 1H), 3.71-3.36 (m, 3H), 0.77 (t, J = 6.8 Hz, 3H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.6, 154.4, 141.9, 134.6, 130.5, 129.5, 128.5, 128.3, 127.3, 127.0, 125.7, 125.0, 122.8, 122.7, 121.1, 119.3, 117.0, 114.3, 112.4, 67.8, 60.4, 49.8, 44.5, 13.6. IR (KBr, v, cm⁻¹) 3430, 3061, 3031, 2978, 2931, 2894, 1716,

1490, 1453, 1229, 1110, 752. HR-MS (ESI-TOF, m/z) calcd for C₂₆H₂₂ClNO₃ [M+Na]⁺ 454.1180, found 454.1191.

Ethyl 2-(5-bromo-1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5h).



White solid, mp 159-160°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.28-8.18 (m, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.35-7.16 (m, 6H), 7.15-7.07 (m, 3H), 7.06-6.76 (m, 3H), 5.61 (d, J = 11.2 Hz, 1H), 4.66-4.58 (m, 1H), 3.81-3.40 (m, 3H), 0.84 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.6, 154.4, 141.9, 134.9, 130.5, 129.5, 128.5, 128.3, 127.6, 127.3, 125.2, 124.9, 122.8, 122.3, 121.1, 117.0, 114.2, 113.3, 112.9, 67.8, 60.4, 49.8, 44.5, 13.6. IR (KBr, v, cm⁻¹) 3430, 3060, 3028, 2979, 2931,

2895, 1718, 1487, 1453, 1230, 1110, 751. HR-MS (ESI-TOF, m/z) calcd for C₂₆H₂₂BrNO₃ [M+Na]⁺ 498.0675, found 498.0670.

Ethyl 2-(5-cyano-1H-indol-3-yl)-4-phenylchromane-3-carboxylate(5i).



White solid, mp111-112°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.67 (s, 1H), 8.05 (s, 1H), 7.47-7.27 (m, 6H), 7.25-7.11 (m, 3H), 7.08-6.78 (m, 3H), 5.66 (d, J = 11.2 Hz, 1H), 4.68-4.61 (m, 1H), 3.79-3.44 (m, 3H), 0.87 (t, J = 7.2 Hz, 3H).¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.4, 154.2, 141.7, 137.9, 130.5, 129.4, 128.8, 128.9, 127.4, 125.9, 125.7, 125.5, 125.2, 122.7, 121.3, 120.7, 116.9, 115.5, 112.4, 103.1, 67.7, 60.5, 49.9, 44.5, 27.0, 13.7. IR (KBr, v, cm⁻¹) 3339, 3061, 3028, 2976, 2931, 2899, 2221,

1725, 1485, 1472, 1227, 1033, 753, 701. HR-MS (ESI-TOF, m/z) calcd for $C_{27}H_{22}N_2O_3$ [M+Na]⁺ 445.1523, found 445.1530.

Ethyl 2-(6-fluoro-1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5j).



White solid, mp 123-124°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.12 (s, 1H), 7.51 (dd, J = 8.8, 5.6 Hz, 1H), 7.31-7.17 (m, 3H), 7.20-7.00 (m, 4H), 7.01-6.70 (m, 5H), 5.58 (d, J = 11.2 Hz, 1H), 4.63-4.38 (m, 1H), 3.76-3.39 (m, 3H), 0.77 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.6, 160.0(d, J = 238.2 Hz), 154.5, 141.9, 136.2 (d, J = 12.3 Hz), 130.4, 129.5, 128.5, 128.3, 127.3, 124.0 (d, J = 3.5 Hz), 123.0, 122.5, 120.60 (d, J = 10.1 Hz), 116.9, 114.6, 108.78 (d, J = 24.2 Hz), 97.7 (d, J = 26.1

Hz), 68.0, 60.3, 49.8, 44.6, 13.6. ¹⁹F NMR (376 MHz, CDCl₃;δ, ppm): -120.8(s). IR (KBr, *ν*, cm⁻¹) 3339, 3062, 3027, 2994, 2889, 1719, 1487, 1453, 1248, 1018, 756. HR-MS (ESI-TOF, m/z) calcd for C₂₆H₂₂FNO₃ [M+Na]⁺ 438.1476, found 438.1478.

Ethyl 2-(6-chloro-1*H*-indol-3-yl)-4-phenylchromane-3-carboxylate(5k).



White solid, mp 142-143°C; ¹H NMR (400 MHz, CDCl₃; δ , ppm) 8.09 (s, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.28-7.19 (m, 4H), 7.17-7.02 (m, 4H), 7.02-6.70 (m, 4H), 5.57 (d, J = 11.2 Hz, 1H), 4.61-4.48 (m, 1H), 3.72-3.37 (m, 3H), 0.77 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃; δ , ppm) 170.5, 154.5, 141.8, 136.6, 130.4, 129.5, 128.7, 128.5, 128.3, 127.3, 124.5, 124.3, 122.9, 121.0, 120.8, 120.7, 116.9, 114.8, 111.3, 67.9, 60.3, 49.8, 44.6, 13.7. IR (KBr, v, cm⁻¹) 3400, 3062, 3027, 2989, 2898, 1715, 1486,

1453, 1244, 1037, 755. HR-MS (ESI-TOF, m/z) calcd for $C_{26}H_{22}CINO_3$ [M+Na]⁺ 454.1180, found 454.1182.













!0 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -22 f1 (ppm)

¹⁹F NMR Spectrum of Compound **3b**

8.073 7.7.513 7.7.513 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.261 7.7.209 7.7.009











¹H NMR Spectrum of Compound **3e**



¹H NMR Spectrum of Compound **3f**











¹⁹F NMR Spectrum of Compound **3h**



¹³C NMR Spectrum of Compound **3i**



¹³C NMR Spectrum of Compound **3**j







¹³C NMR Spectrum of Compound **3**I











¹³C NMR Spectrum of Compound **30**



































¹H NMR Spectrum of Compound **5**e







¹⁹F NMR Spectrum of Compound **5**f

8, 145 8, 145 7, 7, 255 7, 7, 255 7, 7, 255 7, 7, 255 7, 7, 255 7, 7, 256 7, 7, 212 161 17, 221 17, 221 182 182 182 182 193 193 194 195 195 195 195 105</













8,123 7,553 7,553 7,553 7,553 7,553 7,553 7,553 7,553 7,754 7,553 7,754 7,553 7,754 7,150 7,714 7,169 7,714 7,169 7,714 7,169 7,714 7,169 7,714 7,169 7,714 7,169 7,716 7,714 7,169 7,716 7,716 7,716 7,716 7,716 7,716 7,716 7,716 7,716 7,717 7,716 7,717 7,716 7,716 7,717 7,716 7,716 7,716 7,716 7,717 7,169 7,717 7,172 6,696 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,969 6,597 6,597 6,597 6,597 6,597 6,597 6,5966 6,5966 6,5966 6,5966 6,5966 6,5966 6,5966 6,5966 6



¹³C NMR Spectrum of Compound **5**j



 $^1\mathrm{H}$ NMR Spectrum of Compound $\mathbf{5k}$



